PMID 10357824
Some insurance companies have baulked at providing coverage for Wegovy and other GLP-1 agonist drugs for obesity, arguing that the cost is too great unless there is clear evidence of health benefits beyond weight loss
CrossRef Innovative treatments for obesity and NAFLD: A bibliometric study on antioxidants, herbs, phytochemicals, and natural compounds Salvatore Pezzino, Maria Sofia, Chiara Mazzone, Giorgia Litrico, Luigi Piero Greco, Luisa Gallo, Gaetano La Greca, Saverio Latteri Heliyon.2024
Gastroenterology (2004) 127:54658
After decades and decades of every diet known to humankind (and joining Weight Watchers enough times that I probably paid for a new WW office building), I know the problem is not me and my insatiable desire for chocolate
The official FDA approval notice confirms that most side effects are related to digestion or metabolism, not physical structure or injury